|
02 Jun 2023 |
Bluejay Therapeutics Advances in Hepatitis B and D Trials: Successfully Completes BJT-778 Phase 1a Study and Begins Phase 1b Trial Enrollment
|
|
02 Jun 2023 |
Sensei Biotherapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of SNS-101, a Conditionally Active VISTA-blocking Antibody, for the Treatment of Advanced Solid Tumors
|
|
02 Jun 2023 |
TG Therapeutics Announces European Commission Approval for BRIUMVI® (ublituximab-xiiy) for the Treatment of Relapsing Forms of Multiple Sclerosis in Adults
|
|
02 Jun 2023 |
TORL BioTherapeutics Announces Initial Results of Novel Claudin 6 (CLDN6) Targeted Antibody Drug Conjugate (ADC) TORL-1-23 Selected for Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
|
|
02 Jun 2023 |
Clarametyx Announces Positive Early Phase 1 Safety Findings on CMTX-101, Immune-Enabling Antibody Therapy
|
|
02 Jun 2023 |
Lonza to Acquire Synaffix and Strengthen Antibody-Drug Conjugates Offering
|
|
01 Jun 2023 |
Apogenix’ new CD40 agonist HERA-CD40L significantly reduces tumor growth in prostate cancer model
|
|
01 Jun 2023 |
Tonix Pharmaceuticals Announces Presentations Involving TNX-1500 (anti-CD40L mAb) at the 2023 American Transplant Congress
|
|
01 Jun 2023 |
IGM Biosciences Announces FDA Clearance to Begin Clinical Studies of Imvotamab in Lupus and Rheumatoid Arthritis
|
|
01 Jun 2023 |
Celldex Announces First Patient Dosed in Phase 1 Study of CDX-585 in Patients with Advanced Malignancies
|
|
01 Jun 2023 |
Advances of Qilu Pharmaceutical's QL1706 in Clinical Research Presented at ASCO Annual Meeting
|
|
01 Jun 2023 |
Update on brazikumab development programme
|
|
31 May 2023 |
Lupin Announces the Launch of Cetuximab
|
|
31 May 2023 |
Positive Phase 2 data of novel investigational anti-CD40L antibody frexalimab show significantly reduced disease activity in relapsing multiple sclerosis
|
|
31 May 2023 |
Xencor Presents Clinical Results from Phase 1a Study of XmAb®564 at the EULAR 2023 Congress
|
|
31 May 2023 |
Pfizer Announces Positive Marstacimab Results from Pivotal Phase 3 Hemophilia A and B Trial
|
|
29 May 2023 |
Hummingbird Bioscience Announces HMBD-002 Trials in Progress Poster at ASCO Annual Meeting 2023
|
|
29 May 2023 |
Harbour BioMed Reports Results of Phase Ib Clinical Trial of Porustobart in Combination of Toripalimab in Patients with Hepatocellular Carcinoma at ASCO 2023
|
|
27 May 2023 |
ProfoundBio Announces Further Advancement of Lead Programs - PRO1184 (Rinatabart Sesutecan) and PRO1160 in the Clinic
|
|
27 May 2023 |
Imfinzi plus Lynparza and Imfinzi alone both significantly improved progression-free survival in advanced endometrial cancer when added to chemotherapy
|
|
27 May 2023 |
Updated Linvoseltamab (BCMAxCD3) Data from Pivotal Trial Demonstrates Early, Deep and Durable Responses in Patients with Heavily Pre-treated Multiple Myeloma
|
|
26 May 2023 |
Celltrion USA Announces U.S. FDA Approval of Yuflyma (adalimumab-aaty), a High-Concentration and Citrate-Free Formulation of Humira (adalimumab) Biosimilar
|
|
26 May 2023 |
Affimed Announces Publication of AFM24 Clinical Abstracts for the Annual Meeting of the American Society of Clinical Oncology
|
|
26 May 2023 |
Fianlimab (LAG-3 inhibitor) Combined with Libtayo® (cemiplimab) Shows Clinically Meaningful and Durable Tumor Responses Across Key Advanced Melanoma Patient Populations
|
|
26 May 2023 |
Cullinan Oncology to Present First Monotherapy Clinical Data for CLN-619, a Novel Anti-MICA/B Antibody, at ASCO 2023
|
